Equities

Travere Therapeutics Inc

17R:BER

Travere Therapeutics Inc

Actions
  • Price (EUR)17.80
  • Today's Change0.300 / 1.71%
  • Shares traded211.00
  • 1 Year change+239.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 17:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Travere Therapeutics Inc grew revenues 32.69% from 109.46m to 145.24m while net income improved from a loss of 278.48m to a smaller loss of 111.40m.
Gross margin95.21%
Net profit margin-171.52%
Operating margin-175.63%
Return on assets-52.19%
Return on equity-279.94%
Return on investment-69.25%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Travere Therapeutics Inc fell by 3.51m. Cash Flow from Financing totalled 218.75m or 150.62% of revenues. In addition the company used 280.02m for operations while cash from investing totalled 55.78m.
Cash flow per share-3.99
Price/Cash flow per share--
Book value per share-0.3909
Tangible book value per share-1.73
More ▼

Balance sheet in USDView more

Travere Therapeutics Inc has a Debt to Total Capital ratio of 108.75%, a lower figure than the previous year's 134.70%.
Current ratio1.71
Quick ratio1.68
Total debt/total equity--
Total debt/total capital1.09
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.